Pipeline
Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and autoimmune diseases. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
| Program | CAR/ Antigen Target |
Indication | Preclinical | Phase 1/2 | Registrational | Partner |
|---|---|---|---|---|---|---|
| Autoimmunity | ||||||
| FT819 (CDRP) |
CD19 | Lupus Erythematosus (LN) (RMAT) |
FT819-201 (RECLAIM-LN) |
NCT07570862 |
 |
|
| Systemic Lupus Erythematosus (SLE) (RMAT) |
FT819-102 |
NCT06308978 |
||||
| Systemic Sclerosis (SSc) |
FT819-102 |
|||||
| ANCA Associated Vasculitius (AAV) |
FT819-102 |
|||||
| Idiopathis Inflammatory Myopathies (IIM) |
FT819-102 |
|||||
| FT839 | CD19/CD38 | Multicellular Autoimmune, i.e. Rheumatoid Arthritis |
FT839-101 |
|||
| FT522 | CD19 | Autoimmune Indication with mAb |
FT522-102 |
|||
| Oncology | ||||||
| FT825 | HER2 | HER2 Positive Solid Tumors |
FT825-101 |
NCT06241456 |
 |
|
| Undisclosed |
Ongoing R&D activity |
|||||
| FT836 | MICA/B | Pan-tumor Indications, including CRC |
FT836-101 |
NCT07216105 |
|
|
| Multiple Myeloma |
FT836-IIT |
NCT07221032 |
||||
| FT839 | CD19/CD38 | Hematological Malignancies |
IND enabling studies |
|||
Autoimmunity
| Program | CAR/Antigen Target | Indication | Phase |
|---|---|---|---|
| FT819 (CDRP) |
CD19 | Lupus Erythematosus (LN) (RMAT) | Ph 2 FT819-201 (RECLAIM-LN)NCT07570862 |
| Systemic Lupus Erythematosus (SLE) (RMAT) | Ph 1 FT819-102NCT06308978 | ||
| Systemic Sclerosis (SSc) | Ph 1 FT819-102NCT06308978 | ||
| ANCA Associated Vasculitius (AAV) | Ph 1 FT819-102NCT06308978 | ||
| Idiopathis Inflammatory Myopathies (IIM) | Ph 1 FT819-102NCT06308978 | ||
| FT839 | CD19/CD38 | Multicellular Autoimmune, i.e. Rheumatoid Arthritis | Preclinical FT839-101 |
| FT522 | CD19 | Autoimmune Indication with mAb | Ph 1 FT522-102 |
Oncology
| Program | CAR/Antigen Target | Indication | Phase |
|---|---|---|---|
| FT825 |
HER2 | HER2 Positive Solid Tumors | Ph 1 FT825-101NCT06241456 |
| Undisclosed |
Preclinical Ongoing R&D activity | ||
| FT836 |
MICA/B | Pan-tumor Indications, including CRC | Ph1 FT836-101NCT07216105 |
| FT836 |
MICA/B | Multiple Myeloma | Ph1 FT836-IITNCT07221032 |
| FT839 | CD19/CD38 | Hematological Malignancies | Ph1 IND enabling studies |
RMAT = FDA Regenerative Medicine Advanced Therapy (RMAT) received in SLE LCC = Lympho-conditioning chemotherapy CDRP = Chemistry, Manufacturing, and Controls Development and Readiness Pilot US rights to all products